compound introduction
SB-265610 是一种选择性的竞争性非肽变构 CXCR2 拮抗剂。SB-265610 阻断大鼠 CINC-1 诱导的钙动员和中性粒细胞趋化性，IC50 分别为 3.7 nM 和 70 nM。 application： SB265610 has been used: as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR) as a CX-chemokine receptor type 1 (CXCR1) inhibitor to study its effect on the chemotactic activity of chemokines on inflammatory cells as a CXCR2 antagonist to study its effect on migration of neutrophils to the rat brain
